May 3rd, 2023 | 07:30 CEST
Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates
Table of contents:
BioNxt: Strong Newsflow and CEO to speak soon
BioNxt Solutions has gone from strength to strength in recent weeks. The Canadian-German biotech company is making progress in commercializing its products and establishing itself as a contract manufacturer for large pharmaceutical companies. The share price has gained a good 20% since the beginning of the year but still has much room for improvement. The market capitalization is only CAD 60 million.
What is going on at BioNxt? First, a technology for enteric coating of tablets was acquired, and the first prototypes of the coated tablets have already been produced. Then BioNxt's German subsidiary Vektor Pharma TF GmbH in Baden-Württemberg bought modern coating and cutting equipment for commercial mass production. BioNxt is thus on its way to opening up a huge market. This is because administering drugs in the form of tablets reduces costs for the pharmaceutical industry. The interest in BioNxt technology seems to be there: a few days ago, the Canadian-German biotech company reported a new customer. Vektor Pharma TF is to produce an orally soluble product for an international pharmaceutical company. The contract was signed, and the down payment was made.
BioNxt CEO Hugh Rogers said, "The expansion of commercial manufacturing capacity is intended to complement the Company's in-house drug development programmes and provide additional high-quality services to third-party customers preparing for commercialization. The contract signed today is the second such agreement in the past 12 months. We generally view this type of contracting activity as a significant business opportunity with high growth potential."
And BioNxt Solutions has even more hot irons in the fire. The Company has its own active ingredient patch, including the proven active ingredient rotigotine. Its commercialization in the critical US market could be imminent. A US appeals court has confirmed an earlier ruling that the so-called '589 patent for the well-known Parkinson's patch Neupro is invalid. This could be the starting signal for BioNxt's generic patch.
Anyone now curious or already invested should register for the International Investment Forum - IIF - virtual investor conference on May 10 (link https://ii-forum.com), where BioNxt CEO Hugh Rogers will present the Company.
BioNTech: Deutsche Bank reduces price target
Next week it will be exciting again for BioNTech. On May 8, the German biotech pearl will publish quarterly figures. The share could do with new impetus in order not to slip below the EUR 100 mark. While there is little hope for a positive surprise in sales and profits due to the COVID-19 vaccine, investors are hoping for news about the product pipeline. Last year, BioNTech had predicted a brisk newsflow for 2023, but there has been little of that so far. Analysts are correspondingly cautious at the moment. Goldman Sachs has left its rating on BioNTech shares at "Neutral". The price target is USD 140. The analysts see possible positive clinical data on the cancer vaccines currently in development as a price driver. The colleagues at Deutsche Bank are also waiting for this. They rate the BioNTech share as "Hold". The price target was reduced from USD 160 to USD 135 in the last research update.
Bayer: Spin-off, development offensive or takeovers?
A spin-off, development offensive or takeovers? Investors had hoped for answers to this question at last Friday's annual general meeting. But they were disappointed. Although Werner Baumann was not satisfied with the share price either, the outgoing Chairman of the Board of Management did not give any concrete answers. Although Bayer had done comparatively well in the hostile stock market environment of the past year, the stock market value was still well below the Company's actual value, Baumann said. For Baumann, however, one thing is certain: "Bayer has excellent prospects for the future, and I am very sure that this outstanding company still has its best days ahead of it." For at the interface of biology, chemistry and modern data science, new solutions for the problems of our time are emerging.
JPMorgan was also disappointed by the event. Their analysts confirmed their "Neutral" rating yesterday. The price target is EUR 60 and thus the current level of Bayer shares.
The future prospects of Bayer will likely not become more concrete on May 11 either. Then Bayer will report on the first quarter. Werner Baumann, however, will not retire until the end of May after 35 years of service. Then Bill Anderson will take the helm at Bayer. At the Annual General Meeting, the Chairman of the Supervisory Board, Winkeljohann, welcomed the designated Chairman of the Board of Management, who has been a member of the Board since the beginning of the month. He pledged the Supervisory Board's support to Anderson in "unleashing Bayer's full potential and creating sustainable value for our shareholders, farmers, patients, consumers, employees and all company stakeholders". Anderson described the opportunities as immense. He said it was about "translating potential into products, maximizing value with investment and turning vision into value." After Baumann's departure, Anderson can hopefully talk business.
All three companies discussed have important dates coming up. The newsflow at BioNxt is promising, and hopefully, there will be further interesting insights on May 10. Two days before that, things will get exciting at BioNTech. If there is no news on the cancer pipeline, the share threatens to slide below EUR 100. Details on Bayer's future strategy will likely not be available until June, when the old CEO is off the board.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.